All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your Lupus Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
During the 14th European Lupus Meeting 2024, the Lupus Hub was pleased to speak with Ricard Cervera, Hospital Clínic de Barcelona, Barcelona, ES. We asked, What are the management techniques for refractory antiphospholipid syndrome (APS)?
What are the management techniques for refractory antiphospholipid syndrome?
Cervera initiates the discussion by providing an overview of various clinical scenarios of APS. For patients without thrombotic events, primary thromboprophylaxis usually involves low-dose aspirin, while those with thrombotic events receive secondary thromboprophylaxis with oral anticoagulants. Treatment strategies for catastrophic and obstetric APS were also addressed.
Subscribe to get the best content related to lupus delivered to your inbox